

Vinda International Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3331)



2023 Interim Results

*Healthy Lifestyle
Starts with Vinda*





Our Vision

To become Asia's first choice for hygiene products and services



H1 Summary

- Solid sales growth in H1 driven by price, product mix and volume
- Leading market positions
- Strong E-commerce sales growth
- Growth momentum continues in premium categories
- Personal care market positions continue to improve
- Margin recovery in progress but cost pressure yet to subside




¹ YoY growth at constant exchange rates

Financial Highlights




Group Revenue

Total Revenue (HK\$M)



Quarterly Revenue (HK\$M)



Tissue Personal Care



Incontinence



Feminine



Baby




¹ Compound annual growth rate

² YoY growth at constant exchange rates

Growth rate in HKD: +13.1% (FY 2021), +4.0% (FY 2022), +4.0% (H1 2023), +8.8% (Q1 2023), -0.3% (Q2 2023), +8.4% (FY 2022 vs FY 2020 CAGR)

Premium Tissue Portfolio in Mainland China


Organic Growth of Mainland China Premium Tissue Portfolio



Our premium tissue portfolio includes dry tissue of Tempo brand, Vinda Deluxe Soft series, Vinda 4D Deluxe series, Tork brand and wet wipe of all tissue brands.



Group Revenue by Channels




- ▶▶ 23.6% organic growth in E-commerce in H1 2023
- ▶▶ Leading positions in all key E-commerce platforms




Mainland China Revenue and Channel Mix

Total Revenue (HK\$M)


Growth at constant exchange rates



H1 2022



H1 2023




- E-Commerce
- Traditional channels
- B2B
- Key accounts




Gross Profit Margin


Gross Profit (HK\$M)



Gross Profit Margin (%)




Pulp Market Price Movement




- ❖ Favorable contribution from price/mix
- ❖ Gradual improvement in material costs

Operating Profit & EBITDA


Operating Profit (HK\$M)




Operating Margin (%)



EBITDA (HK\$M)





EBITDA Margin (%)





Segment Performance

Revenue Mix (%)





● Personal Care ● Tissue

Revenue (HK\$M)



Gross profit margin (%)




¹ YoY growth at constant exchange rates

² Growth rate in HKD: +5.0% (Tissue, H1 2023), -0.5% (Personal Care, H1 2023)

SG&A

SG&A as a % of Sales




- Efficiency improvement on administrative activities
- Initiatives in place to improve investment ROI
- Committed to continuous brand building of personal care brands and premium categories
- Continue to invest in new channels to drive growth and penetration




* Including net impairment losses on financial assets

Net Profit, Interest Rate & Dividend


Net Profit (HK\$M)




Basic Earnings Per Share (HK cents per share)




Effective Interest Rate (%)



Net Profit Margin (%)



Proposed Interim Dividend (HK cents per share)



Key Indicators

	As at 31 Dec 2022	As at 30 Jun 2023
Debtors turnover days ¹	40	40
Creditors turnover days ²	71	88
Finished goods turnover days ³	50	57
Working capital to sales ratio ⁴	6.6%	13.1%
(HK\$M)	As at 31 Dec 2022	As at 30 Jun 2023
Cash and cash equivalents	607	838
Total borrowings & lease liabilities	4,043	5,719
Net debt	3,436	4,881
Net gearing ratio ⁵	28.6%	43.1%
Net debt/EBITDA	1.6	3.2
(HK\$M)	FY 2022	H1 2023
CAPEX	1,102	474

¹ Multiplying 12-month average account receivables by 360 days and dividing the result by the revenue for the last 12 months


² Multiplying 12-month average account payables by 360 days, and dividing the result by the cost of sales for the last 12 months

³ Multiplying 12-month average finished goods by 360 days, and dividing the result by the cost of sales for the last 12 months

⁴ Total working capital (excl. cash & cash equivalents)/ rolling 12 months revenue

⁵ Net gearing ratio: net debt / total shareholders' equity

Sustainable Development



2022 Recognition

Outstanding Award for Green and Sustainable Loan Issuer
傑出綠色和可持續貸款發行機構

Pioneering Organisation in ESG Disclosure Enhancement
ESG 披露優化先鋒機構

MSCI ESG RATINGS **A**

CCC B BB BBB A AA AAA


Hang Seng Corporate Sustainability Index Series Member 2022-2023

* The sum of progress made in 2021 and 2022 for the Vinda Five-Year Sustainable Development Target 2021-2025

Appendix



Production Capacity Plan



Tissue annual designed production capacity

1.39 M tons
(2023)

- New production plant in Zhejiang factory has been put in production since 2H 2022. And it will further increase tissue production capacity in 2023.

Personal care facility

- The new Southeast Asia regional headquarters, state-of-the-art production facilities, first-class warehouse and distribution centre and modern innovation centre in Malaysia is well operating as planned.
- China personal care facilities locate in East China and Central China and Chinese Taiwan.

Financial Highlights Summary

(HK\$M)	H1 2022	H1 2023	YOY
Revenue	9,680	10,070	+4.0%
<i>Growth at constant exchange rates</i>	<i>+6.9%</i>	<i>+10.1%</i>	
Gross profit	3,100	2,527	-18.5%
<i>Gross margin</i>	<i>32.0%</i>	<i>25.1%</i>	<i>-6.9ppts</i>
Operating profit	757	137	-81.8%
<i>Operating margin</i>	<i>7.8%</i>	<i>1.4%</i>	<i>-6.4ppts</i>
EBITDA	1,418	818	-42.3%
<i>EBITDA margin</i>	<i>14.6%</i>	<i>8.1%</i>	<i>-6.5ppts</i>
Net profit	638	121	-81.1%
<i>Net margin</i>	<i>6.6%</i>	<i>1.2%</i>	<i>-5.4ppts</i>
Basic EPS (HK cents)	53.0	10.0	
Proposed interim dividend per share (HK cents)	10.0	10.0	

H2 2022	HOH
9,737	+3.4%
	<i>+2.6%</i>
2,383	+6.0%
<i>24.5%</i>	<i>+0.6ppt</i>
50	+177.0%
<i>0.5%</i>	<i>+0.9ppt</i>
686	+19.3%
<i>7.0%</i>	<i>+1.1ppts</i>
68	+76.6%
<i>0.7%</i>	<i>+0.5ppt</i>

Q&A



Disclaimer

Information contained in our presentation is intended solely for your personal reference and is strictly confidential. You may not reproduce, redistribute or pass on, directly or indirectly, this presentation to any other person or publish, in whole or in part, for any purpose. The distribution of this presentation may be restricted by law, and persons who come into possession of this presentation should inform themselves about, and observe, such restrictions.

Information in this presentation is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning the company and/or its business. We make no representation or warranty, express or implied, regarding and no reliance should be placed on the fairness, accuracy, correctness, reasonableness or completeness of, or any errors or omissions in, any information, opinions, estimates, forecasts and projections contained herein.

In addition, the information contains projections and forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the company's assumptions are correct. Actual results may differ materially from those projected. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects. We accept no liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.

This presentation does not constitute an offer or invitation to acquire, purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.